Insider Transactions in Q2 2024 at Mirum Pharmaceuticals, Inc. (MIRM)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2024
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
30,559
-52.72%
|
$1,039,006
$34.0 P/Share
|
|
Jun 24
2024
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,559
+34.52%
|
$61,118
$2.94 P/Share
|
|
Jun 05
2024
|
Saira Ramasastry |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$125,000
$25.68 P/Share
|
|
Jun 05
2024
|
Saira Ramasastry |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$70,000
$14.12 P/Share
|
|
May 10
2024
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
94
+0.34%
|
$1,974
$21.05 P/Share
|
|
May 10
2024
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
817
+0.87%
|
$17,157
$21.05 P/Share
|
|
May 10
2024
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
470
+3.15%
|
$9,870
$21.05 P/Share
|